Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in <font color="red">patients_5</font> <font color="red">with_5</font> <font color="red">mixed_5</font> <font color="red">dyslipidaemia_5</font> <font color="red">and_5</font> <font color="red">metabolic_5</font> <font color="red">syndrome_5</font> <font color="red">._5</font> 
<br>
<br> BACKGROUND Raised triglycerides ( TG ) , decreased high - density lipoprotein cholesterol ( HDL - C ) levels and a predominance of small dense low density lipoproteins ( sdLDL ) are characteristics of the <font color="red">metabolic_2</font> <font color="red">syndrome_2</font> <font color="red">(_2</font> <font color="red">MetS_2</font> <font color="red">)_2</font> <font color="red">._2</font> 
<br> OBJECTIVE To compare the effect of high - dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in <font color="red">patients_3</font> <font color="red">with_3</font> <font color="red">mixed_3</font> <font color="red">dyslipidaemia_3</font> <font color="red">and_3</font> <font color="red">MetS._3</font> 
<br> METHODS We previously <font color="red">randomised_1</font> <font color="red">patients_3</font> <font color="red">with_3</font> <font color="red">low_3</font> <font color="red">-_3</font> <font color="red">density_3</font> <font color="red">lipoprotein_3</font> <font color="red">cholesterol_3</font> <font color="red">(_3</font> <font color="red">LDL_3</font> <font color="red">-_3</font> <font color="red">C_3</font> <font color="red">)_3</font> <font color="red">>_3</font> <font color="red">160_3</font> <font color="red">and_3</font> <font color="red">TG_3</font> <font color="red">>_3</font> <font color="red">200_3</font> <font color="red"> _3</font> <font color="red">mg_3</font> <font color="red">/_3</font> <font color="red">dl_3</font> <font color="red">to_2</font> <font color="red">rosuvastatin_2</font> <font color="red">monotherapy_2</font> <font color="red">40_2</font> <font color="red"> _2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">day_2</font> <font color="red">(_2</font> <font color="red">R_2</font> <font color="red">group_2</font> <font color="red">,_2</font> <font color="red">n_3</font> <font color="red">=_3</font> <font color="red">30_3</font> <font color="red">)_3</font> <font color="red">or_2</font> <font color="red">rosuvastatin_2</font> <font color="red">10_2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">day_2</font> <font color="red">combined_2</font> <font color="red">with_2</font> <font color="red">fenofibrate_2</font> <font color="red">200_2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">day_2</font> <font color="red">(_2</font> <font color="red">RF_2</font> <font color="red">group_2</font> <font color="red">,_2</font> <font color="red">n_3</font> <font color="red">=_3</font> <font color="red">30_3</font> <font color="red">)_3</font> <font color="red">or_2</font> <font color="red">ω-3_2</font> <font color="red">fatty_2</font> <font color="red">acids_2</font> <font color="red">2_2</font> <font color="red">g_2</font> <font color="red">/_2</font> <font color="red">day_2</font> <font color="red">(_2</font> <font color="red">Rω_2</font> <font color="red">group_2</font> <font color="red">,_2</font> <font color="red">n_3</font> <font color="red">=_3</font> <font color="red">30_3</font> <font color="red">)_3</font> <font color="red">._2</font> <font color="red">In_1</font> <font color="red">the_1</font> <font color="red">present_1</font> <font color="red">study_1</font> <font color="red">,_1</font> <font color="red">only_3</font> <font color="red">patients_3</font> <font color="red">with_3</font> <font color="red">MetS_3</font> <font color="red">were_3</font> <font color="red">included_3</font> <font color="red">(_2</font> <font color="red">24_2</font> <font color="red">,_2</font> <font color="red">23_2</font> <font color="red">and_2</font> <font color="red">24_2</font> <font color="red">in_2</font> <font color="red">the_2</font> <font color="red">R_2</font> <font color="red">,_2</font> <font color="red">RF_2</font> <font color="red">and_2</font> <font color="red">Rω_2</font> <font color="red">groups_2</font> <font color="red">respectively_2</font> <font color="red">)_2</font> <font color="red">._2</font> At baseline and after 12 weeks of treatment , the lipoprotein subfraction profile was determined by polyacrylamide 3% gel electrophoresis . 
<br> RESULTS The mean LDL size was significantly increased in all groups . This change was more prominent with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05 compared with R and Rω ) . A decrease in insulin resistance by RF was also noted . Only RF significantly raised HDL - C levels ( by 7.7% , p < 0.05 ) by increasing the cholesterol of small HDL particles . The cholesterol of larger HDL subclasses was significantly increased by R and Rω. 
<br> CONCLUSIONS All regimens increased mean LDL size ; RF was the most effective . A differential effect of treatments was noted on the HDL subfraction profile .